Lowering The Lipids Barrier: The Key To Accelerating RNA-LNP Drug Development

The remarkable success of LNP-based mRNA technology in combating SARS-CoV-2 has made it one of the most exciting fields in medicine right now. mRNA's potential to enable highly rapid and scalable drug development is a key reason why it is considered such a significant breakthrough. Since precise tuning is required for lipid nanoparticle compositions to deliver payload efficiently, developers need solutions that simplify and streamline the complex, lengthy processes involved in lipid candidate selection and LNP composition optimization.

In this white paper, you will learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA. The challenge of selecting and optimizing a successful ionizable lipid mix in the early development stages is the primary focus, and the paper explores the amount of time required when starting from scratch in this process. Further, it examines the benefits of off-the-shelf ionizable lipids and reagent kits that have been pre-developed and pre-optimized for a diverse range of genomic medicine applications. Finally, the white paper seeks to quantify how much faster a new nanomedicine-based drug candidate could be brought to the clinic with access to the portfolio of ionizable lipids and reagent kits developed by Precision NanoSystems.